This invention relates to the discovery that members of the pyrrolotriazinyl class of IGF-1R kinase inhibitors also are inhibitors of the NCTP transporter and block taurocholic acid entry into hepatocytes. An IGF-1R kinase inhibitor such as described in U.S.P. 7,534,792, especially BMS-754807, blocks the NTCP transporter and is therefore useful in preventing Hepatitis B disease, cirrhosis, and hepatic cellular cancer. This preferred compound is (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide.
展开▼
